Edward M. MD Kaye - Mar 18, 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Mar 18, 2025
Transactions value $
-$163,673
Form type
4
Date filed
3/20/2025, 06:15 PM
Previous filing
Mar 18, 2025
Next filing
Apr 16, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Sale -$90K -10.4K -6.54% $8.67 148K Mar 18, 2025 Direct F1, F2
transaction STOK Common Stock Sale -$73.7K -8.91K -6.01% $8.27 139K Mar 19, 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Employee Stock Option (Right to Buy) Award $0 +216K $0.00 216K Mar 20, 2025 Common Stock 216K $8.33 Direct F4
transaction STOK Restricted Stock Units Award $0 +144K $0.00 144K Mar 20, 2025 Common Stock 144K Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.11 to $8.925 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 3.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.06 to $8.95 per share, inclusive.
F4 The option shall vest as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
F5 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F6 The award vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date.